Innoviva, INC 10-Q quarterly reports

Innoviva, Inc. announced Q1 2026 results with total revenue of $98.0 million, a 11% increase year-over-year, driven by growth in net product sales and significant gains from strategic investments.

Innoviva reports a substantial increase in net income and product sales for Q3 2025, driven by commercialization efforts and strategic investments, alongside a new share repurchase program.

Innoviva, Inc. reported a significant turnaround in net income for Q2 2025, driven by robust growth in net product sales and favorable changes in investment fair values, alongside key pipeline advancements.

Innoviva's Q1 2025 saw stable royalty revenue, a significant increase in product sales, but a net loss due to unfavorable changes in the fair value of equity and long-term investments.

Innoviva's Q3 2024 results show revenue growth driven by increased product sales and royalties from partnered respiratory assets.

Innoviva's second quarter results show a mix of increased product sales and royalty revenue alongside significant investment losses.

Innoviva's first quarter 2024 results show revenue growth driven by increased royalty revenue from respiratory assets and strong performance in product sales, particularly XACDURO.